Praxis Precision Medicines Inc Cash Flow Conversion Efficiency
Praxis Precision Medicines Inc cash flow conversion efficiency. Based on the latest financial reports, Praxis Precision Medicines Inc (PRAX) has a cash flow conversion efficiency ratio of -0.058x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-77.64 Million) by net assets ($1.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Praxis Precision Medicines Inc (2018–2025)
Cash flow conversion efficiency of Praxis Precision Medicines Inc from 2018 to 2025. This chart illustrates how Praxis Precision Medicines Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Praxis Precision Medicines Inc (PRAX) share price today for real-time trading data and today's change.
Praxis Precision Medicines Inc Cash Flow Conversion Ratio Explained
Praxis Precision Medicines Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Praxis Precision Medicines Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Praxis Precision Medicines Inc ranked by their cash flow conversion efficiency. Also see Praxis Precision Medicines Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Hi-speed Co Ltd
SHG:600350
|
0.028x |
|
The Hanover Insurance Group Inc
NYSE:THG
|
0.058x |
|
Vicinity Centres
AU:VCX
|
0.028x |
|
Full Truck Alliance Co Ltd ADR
NYSE:YMM
|
0.038x |
|
Itissalat Al-Maghrib (IAM) S.A
F:MSPA
|
0.151x |
|
AXIS Capital Holdings Ltd
NYSE:AXS
|
0.106x |
|
Janus Henderson Group PLC
NYSE:JHG
|
0.041x |
|
Simpson Manufacturing Company Inc
NYSE:SSD
|
0.101x |
Annual Cash Flow Conversion Efficiency for Praxis Precision Medicines Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Praxis Precision Medicines Inc from 2018 to 2025. Review financial agility of Praxis Precision Medicines Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $878.14 Million | $-249.07 Million | -0.284x | +4.11% |
| 2024-12-31 | $445.45 Million | $-131.76 Million | -0.296x | +81.46% |
| 2023-12-31 | $69.67 Million | $-111.14 Million | -1.595x | +34.39% |
| 2022-12-31 | $76.11 Million | $-185.04 Million | -2.431x | -389.60% |
| 2021-12-31 | $250.81 Million | $-124.55 Million | -0.497x | -171.27% |
| 2020-12-31 | $287.46 Million | $-52.62 Million | -0.183x | +77.60% |
| 2019-12-31 | $40.11 Million | $-32.79 Million | -0.817x | +42.09% |
| 2018-12-31 | $14.68 Million | $-20.72 Million | -1.411x | -- |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more